Solid stock: buy or sell?

SLDB stock price: $3.68 5.44% At close on November 19th, 2019

Updated on:
November 19th, 2019


On November/12 SLDB plunged a frightening -290.07%. Solid closed today at $3.68 and climbed an amazing 5.44%.

Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States.

Should I buy Solid stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Solid stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Solid stock a buy?

Financial institutions and banks post stock ratings everyday. At, we collected 9 ratings published for SLDB stock in the last month.

Is SLDB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-19Svb LeerinkMarket PerformOutperform
2019-8-19Leerink SwannMarket PerformOutperform
2019-8-16Chardan CapitalNeutralBuy
2019-5-14Goldman Sachs GroupNeutralSell
2019-5-14Credit Suisse GroupNeutralUnderperform
2019-2-8Svb LeerinkOutperformMarket Perform
2019-2-7Chardan Capitaln/aBuy

Solid stock analysis

Daily outlook

Solid Biosciences climbed an amazing 5.44% and closed at $3.68.

Solid closed today at $3.68 and climbed an amazing 5.44%. Since SMA100d and SMA200d crossed up today, SLDB price climbed $0.19 per share (5.44%). For the last 7 days when SLDB stock price broke down the SMA200d line, it slid $-7.32 per share (-66.55%).

SLDB stock chart (daily)

Weekly outlook

Last week SLDB plunged a dreadful -214.25% in just one week. After sliding a dreadful -214.25% in a week last week, Solid Biosciences closed this week at $3.68 and climbed a phenomenal 4.84%.

Since last week, when SLDB stock price broke down the 40-weeks moving avarage line, it slid $-7.35 per share (-66.64%). Stocks under the 200 days moving average line are usually not recommended for average traders. Since early November when SMA20w and SMA40w crossed up, SLDB price slipped $-7.85 per share (-68.08%).

SLDB stock chart (weekly)

Solid stock price history

Solid stock went public on January 26th, 2018 with a price of $25.501. Since then, SLDB stock sliced a -85.60%, with a yearly average of -85.60%.

1: Adjusted price after possible price splits or reverse-splits.

Solid stock historical price chart

SLDB stock reached 52-week highs at $35.00, and all-time highs 2018-06-19 with a price of 54.84.

Solid stock price target is $9.30

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We detected 4 price targets for Solid Biosciences stock released in the last month:
SLDB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-16Chardan CapitalUpgrades$7.50$10.0033.3%
2019-5-14Credit Suisse GroupDowngrades$7.00$6.00-14.3%
2019-2-7Chardan CapitalReiteratesn/a$15.00-
(in average)$7.30$9.3027.0%
The price prediction for Solid stock is $9.30, moving in a range between $15.00 and $6.00. In average, analysts' outlook on SLDB price forecast is positive, improving the forecast by a 27.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Solid Biosciences presented its financial report, posting a very good climb for the Earnings per Share (EPS). Analyst were expecting $-0.58 per share, but Solid posted $-0.67.
SLDB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In , Solid Biosciences annual revenues to M dollars from marked in . , its earnings margin (compared to sales) to , that is million.

SLDB annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-21.92 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Solid Biosciences sales marked a tight movement and stayed steady a nan%. Looking back to recent quarterly results, Solid Biosciences posted 5 negative quarters in a row.
SLDB quarterly Sales and Income evolution

Solid ownership

When you are planning to invest in a company, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Solid, 34.71% of all outstanding shares are owned by its staff.

In case of Solid Biosciences stock, 77.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SLDB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Solid:

Market cap$169.3 M
Total shares46.0 M
Float shares11.1 M
  - Institutional holdings (%)77.4%
  - Insider holdings (%)34.7%
Shares in short selling0.0%

Solid summary

Tuesday, November 19th, 2019
Day range$3.33 - $3.80
Previous close$3.49
Session gain5.44%
Average true range$1.16
50d mov avg$10.02
100d mov avg$8.34
200d mov avg$8.30
Daily patternlt03a
Weekly pattern

Solid performance

To better understand Solid Biosciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Solid, the benchmark is made against .
SLDBSolid Biosciences-57.75%-33.33%-88.37%

Solid competitors

Unfortunately, we could not find any public company that could be defined as Solid competitor. This doesn't mean Solid does not have any competitor in the market, it's just we could not detected it.